13 July 2022 : Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak1ACDEF*, Marcin Mazurek1BCEF, Aleksandra Majdan
1DEF, Radosław Mlak1ACDE, Maria Majdan 2ADEF, Teresa Mełecka-Massalska1ADEF
DOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 1 General characteristic of the study group.
| Variable | n (%) or median (range) | |
|---|---|---|
| Study group (n=59) | Control group (n=52) | |
| Male | 8 (13.56%) | 8 (15.38%) |
| Female | 51 (86.44%) | 44 (84.62%) |
| Age (years) | 36.5 (19–72) | 38.0 (22–64) |
| Duration of the disease (years) | 6 (0–37) | – |
| SLEDAI | ||
| Mild | 51 (86.4%) | – |
| Moderate | 6 (10.17%) | – |
| Severe | 2 (3.39%) | – |
| n – number, SLEDAI – Systemic Lupus Erythematosus Disease Activity Index. | ||